GMED Quote, Financials, Valuation and Earnings

Merit Medical Systems, Inc. has a net margin of 15.47% compared to Globus Medical, Inc.'s net margin of 7.22%. Globus Medical, Inc.'s return on equity of 10.08% beat Merit Medical Systems, Inc.'s return on equity of 8.28%.

Globus Medical, Inc. has a consensus price target of $91.70, signalling upside risk potential of 3.34%. On the other hand Merit Medical Systems, Inc. has an analysts' consensus of $102.50 which suggests that it could grow by 21.89%. Given that Merit Medical Systems, Inc. has higher upside potential than Globus Medical, Inc., analysts believe Merit Medical Systems, Inc. is more attractive than Globus Medical, Inc..

Globus Medical, Inc. has a beta of 1.070, which suggesting that the stock is 7.046% more volatile than S&P 500. In comparison Merit Medical Systems, Inc. has a beta of 0.615, suggesting its less volatile than the S&P 500 by 38.504%.

Globus Medical, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merit Medical Systems, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Globus Medical, Inc. pays -- of its earnings as a dividend. Merit Medical Systems, Inc. pays out -- of its earnings as a dividend.

Globus Medical, Inc. quarterly revenues are $769M, which are larger than Merit Medical Systems, Inc. quarterly revenues of $384.3M. Globus Medical, Inc.'s net income of $119M is higher than Merit Medical Systems, Inc.'s net income of $27.8M. Notably, Globus Medical, Inc.'s price-to-earnings ratio is 28.68x while Merit Medical Systems, Inc.'s PE ratio is 43.04x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Globus Medical, Inc. is 4.42x versus 3.45x for Merit Medical Systems, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Insulet Corp. has a net margin of 15.47% compared to Globus Medical, Inc.'s net margin of 12.4%. Globus Medical, Inc.'s return on equity of 10.08% beat Insulet Corp.'s return on equity of 18.92%.

Globus Medical, Inc. has a consensus price target of $91.70, signalling upside risk potential of 3.34%. On the other hand Insulet Corp. has an analysts' consensus of $378.21 which suggests that it could grow by 19.72%. Given that Insulet Corp. has higher upside potential than Globus Medical, Inc., analysts believe Insulet Corp. is more attractive than Globus Medical, Inc..

Globus Medical, Inc. has a beta of 1.070, which suggesting that the stock is 7.046% more volatile than S&P 500. In comparison Insulet Corp. has a beta of 1.374, suggesting its more volatile than the S&P 500 by 37.428%.

Globus Medical, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insulet Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Globus Medical, Inc. pays -- of its earnings as a dividend. Insulet Corp. pays out -- of its earnings as a dividend.

Globus Medical, Inc. quarterly revenues are $769M, which are larger than Insulet Corp. quarterly revenues of $706.3M. Globus Medical, Inc.'s net income of $119M is higher than Insulet Corp.'s net income of $87.6M. Notably, Globus Medical, Inc.'s price-to-earnings ratio is 28.68x while Insulet Corp.'s PE ratio is 91.66x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Globus Medical, Inc. is 4.42x versus 9.07x for Insulet Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Solventum Corp. has a net margin of 15.47% compared to Globus Medical, Inc.'s net margin of 60.4%. Globus Medical, Inc.'s return on equity of 10.08% beat Solventum Corp.'s return on equity of 42.2%.

Globus Medical, Inc. has a consensus price target of $91.70, signalling upside risk potential of 3.34%. On the other hand Solventum Corp. has an analysts' consensus of $84.36 which suggests that it could fall by -1.05%. Given that Globus Medical, Inc. has higher upside potential than Solventum Corp., analysts believe Globus Medical, Inc. is more attractive than Solventum Corp..

Globus Medical, Inc. has a beta of 1.070, which suggesting that the stock is 7.046% more volatile than S&P 500. In comparison Solventum Corp. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Globus Medical, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Solventum Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Globus Medical, Inc. pays -- of its earnings as a dividend. Solventum Corp. pays out -- of its earnings as a dividend.

Globus Medical, Inc. quarterly revenues are $769M, which are smaller than Solventum Corp. quarterly revenues of $2.1B. Globus Medical, Inc.'s net income of $119M is lower than Solventum Corp.'s net income of $1.3B. Notably, Globus Medical, Inc.'s price-to-earnings ratio is 28.68x while Solventum Corp.'s PE ratio is 9.81x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Globus Medical, Inc. is 4.42x versus 1.77x for Solventum Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Stryker Corp. has a net margin of 15.47% compared to Globus Medical, Inc.'s net margin of 14.18%. Globus Medical, Inc.'s return on equity of 10.08% beat Stryker Corp.'s return on equity of 14.06%.

Globus Medical, Inc. has a consensus price target of $91.70, signalling upside risk potential of 3.34%. On the other hand Stryker Corp. has an analysts' consensus of $429.31 which suggests that it could grow by 17.83%. Given that Stryker Corp. has higher upside potential than Globus Medical, Inc., analysts believe Stryker Corp. is more attractive than Globus Medical, Inc..

Globus Medical, Inc. has a beta of 1.070, which suggesting that the stock is 7.046% more volatile than S&P 500. In comparison Stryker Corp. has a beta of 0.890, suggesting its less volatile than the S&P 500 by 11.047%.

Globus Medical, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Stryker Corp. offers a yield of 0.92% to investors and pays a quarterly dividend of $0.84 per share. Globus Medical, Inc. pays -- of its earnings as a dividend. Stryker Corp. pays out 41.74% of its earnings as a dividend. Stryker Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Globus Medical, Inc. quarterly revenues are $769M, which are smaller than Stryker Corp. quarterly revenues of $6.1B. Globus Medical, Inc.'s net income of $119M is lower than Stryker Corp.'s net income of $859M. Notably, Globus Medical, Inc.'s price-to-earnings ratio is 28.68x while Stryker Corp.'s PE ratio is 47.84x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Globus Medical, Inc. is 4.42x versus 5.77x for Stryker Corp.. Usually stocks with elevated PS ratios are considered overvalued.